Ertapenem blood concentration: A retrospective cohort study to analyse risk of neurotoxicity.
ertapenem
neurotoxicity
plasma trough concentration
therapeutic drug monitoring
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
20
04
2023
received:
20
10
2022
accepted:
04
05
2023
medline:
16
8
2023
pubmed:
12
5
2023
entrez:
12
5
2023
Statut:
ppublish
Résumé
Several cases of ertapenem-related neurotoxicity have been published in the current literature. However, studies evaluating the ertapenem blood concentration (EBC) as a risk of these adverse events are scarce. We aimed to evaluate the relationship between the trough EBC and the risk of neurological toxicity. This was a retrospective study, including patients who underwent ertapenem treatment between October 2019 and February 2021. We excluded patients in the critical care unit and those whose blood samples were not properly taken in order to analyse ertapenem trough concentration. We also excluded patients whose clinical follow-up was not properly realized for the entire period of ertapenem treatment. The main outcome was the presence of any suspicious neurological side effect owing to ertapenem administration and its relationship with the plasma concentration. Secondary outcomes were to identify clinical and analytical data contributing to a higher risk of neurotoxicity. The initial cohort comprised 158 individuals. For the final analysis we evaluated 102 patients, reporting a neurological alteration in 13/102 (12.7%). Mean trough EBC was significantly higher in patients showing neurotoxicity in comparison with those who did not (37.8 mcg mL In patients at risk, determining the ertapenem plasma concentration may help to minimize the risk of neurotoxicity.
Substances chimiques
Ertapenem
G32F6EID2H
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2843-2850Informations de copyright
© 2023 British Pharmacological Society.
Références
Deshayes S, Coquerel A, Verdon R. Neurological adverse effects attributable to beta-lactam antibiotics: a literature review. Drug Saf. 2017;40(12):1171-1198. doi:10.1007/s40264-017-0578-2
European Medicines Agency. Invanz-INN Ertapenem. Product information. Accessed March 24, 2021. https://www.ema.europa.eu/documents/product-information/invanz-epar-product-information_en.pdf
Lee KH, Ueng YF, Wu CW, Chou YC, Ng YY, Yang WC. The recommended dose of ertapenem poses a potential risk for central nervous system in haemodialysis patients-case reports and literature reviews. J Clin Pharm and Ther. 2015;40(2):240-244. doi:10.1111/jcpt.12239
el Nekidy WS, Elrefaei H, St. John TJL, et al. Ertapenem neurotoxicity in hemodialysis patients-safe and effective dosing is still needed. Ann Pharmacother. 2021;55(1):52-58. doi:10.1177/1060028020938059
Duquaine S, Kitchell E, Tate T, Tannen RC, Wickremasinghe IM. Central nervous toxicity associated with ertapenem use. Ann Pharmacother. 2011;45(1):e6. doi:10.1345/aph.1P528
Shea YF, Maggie Mok MY, Cheng KC, Sonny Hon FK, Chu LW. Delayed recovery from ertapenem induced encephalopathy: case-report and a possible mechanism. Int J Clin Pharmacol. 2013;35(4):535-537. doi:10.1007/s11096-013-9812-x
Oo Y, Packham D, Yau W, Munckof WJ. Ertapenem-associated psychosis and encephalopathy. Int Med J. 2014;44(8):817-819. doi:10.1111/imj.12504
Veillette JJ, Van Epps P. Ertapenem-induced hallucinations and delirium in an elderly patient. Consult Pharm. 2016;31(4):207-214. doi:10.4140/TCP.n.2016.207
Sutton SS, Jumper M, Cook S, Edun B, Wyatt MD. Ertapenem-induced encephalopathy in a patient with normal renal function. J Investig Med High Impact Case Rep. 2017;5(1):2324709616689376. doi:10.1177/2324709616689376
Adams R, Chopra P, Miranda R, Calderon A. Ertapenem-induced encephalopathy. BMJ Case Rep. 2020;13(6):e231875. doi:10.1136/bcr-2019-231875
Danés I, Pérez E, Pigrau C, et al. A case series of confusional states and other neurotoxic effects caused by ertapenem. Br J Clin Pharmacol. 2021;87(4):2140-2145. doi:10.1111/bcp.14582
Lee YC, Huang YJ, Hung MC, et al. Risk factors associated with the development of seizures among adult patients treated with ertapenem: a matched case-control study. PLoS ONE. 2017;12(7):e0182046. doi:10.1371/journal.pone.0182046
Cottagnoud P, Pfister M, Cottagnoud M, Acosta F, Täuber MG. Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother. 2003;47(6):1943-1947. doi:10.1128/AAC.47.6.1943-1947.2003
National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0. National Cancer Institute; 2017.
Karch F, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977;21(3):247-254. doi:10.1002/cpt1977213247
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. doi:10.7326/0003-4819-150-9-200905050-00006
Pickering M, Brown S. Quantification and validation of HPLC-UV and LC-MS assays for therapeutic drug monitoring of ertapenem in human plasma. Biomed Chromatogr. 2013;27(5):568-574. doi:10.1002/bmc.2829
Chow KM, Szeto CC, Hui ACF, Li PKT. Mechanisms of antibiotic neurotoxicity in renal failure. Int J Antimicrob Agents. 2004;23(3):213-217. doi:10.1016/j.ijantimicag.2003.11.004
Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011;72(3):381-393. doi:10.1111/j.1365-2125.2011.03991.x
Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizures rates, and clinical considerations. Pharmacotherapy. 2011;31(4):408-423. doi:10.1592/phco.31.4.408
Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother. 2004;53(suppl_2):ii23-ii28. doi:10.1093/jac/dkh205
Zusman O, Farbman L, Tredler Z, et al. Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study. Clin Microbiol Infect. 2015;21(1):21-58. doi:10.1016/j.cmi.2014.08.003
Devaraj S. Albumin. Accesed December 13, 2021. https://emedicine.medscape.com/article/2054430-overview
Varallo FR, Planeta CS, Herdeiro MT, Mastroianni PC. Imputation of adverse drug reactions: causality assessment in hospitals. PLoS ONE. 12(2):e0171470. doi:10.1371/journal.pone.0171470